156 related articles for article (PubMed ID: 7498327)
21. Ascorbic acid reduces the dopamine depletion induced by MPTP.
Wagner GC; Jarvis MF; Carelli RM
Neuropharmacology; 1985 Dec; 24(12):1261-2. PubMed ID: 3879339
[TBL] [Abstract][Full Text] [Related]
22. Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) and methamphetamine.
Jarvis MF; Wagner GC
Life Sci; 1985 Jan; 36(3):249-54. PubMed ID: 3871245
[TBL] [Abstract][Full Text] [Related]
23. Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide.
Cosi C; Marien M
Brain Res; 1998 Oct; 809(1):58-67. PubMed ID: 9795136
[TBL] [Abstract][Full Text] [Related]
24. Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
Knaryan VH; Samantaray S; Varghese M; Srinivasan A; Galoyan AA; Mohanakumar KP
Neuropeptides; 2006 Aug; 40(4):291-8. PubMed ID: 16712929
[TBL] [Abstract][Full Text] [Related]
25. Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice.
Kitamura Y; Itano Y; Kubo T; Nomura Y
J Neuroimmunol; 1994 Mar; 50(2):221-4. PubMed ID: 7509816
[TBL] [Abstract][Full Text] [Related]
26. Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra.
Ricaurte GA; Irwin I; Forno LS; DeLanney LE; Langston E; Langston JW
Brain Res; 1987 Feb; 403(1):43-51. PubMed ID: 3493827
[TBL] [Abstract][Full Text] [Related]
27. The effects of deprenyl on methamphetamine-induced dopamine depletions.
Johnson SK; Medina D; Wagner GC
J Neural Transm Gen Sect; 1992; 89(1-2):123-7. PubMed ID: 1418863
[TBL] [Abstract][Full Text] [Related]
28. Genetic or pharmacological blockade of noradrenaline synthesis enhances the neurochemical, behavioral, and neurotoxic effects of methamphetamine.
Weinshenker D; Ferrucci M; Busceti CL; Biagioni F; Lazzeri G; Liles LC; Lenzi P; Pasquali L; Murri L; Paparelli A; Fornai F
J Neurochem; 2008 Apr; 105(2):471-83. PubMed ID: 18042179
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.
German DC; Liang CL; Manaye KF; Lane K; Sonsalla PK
Neuroscience; 2000; 101(4):1063-9. PubMed ID: 11113355
[TBL] [Abstract][Full Text] [Related]
30. Intrastriatal injection of 5,7-dihydroxytryptamine decreased 5-HT levels in the striatum and suppressed locomotor activity in C57BL/6 mice.
Chia LG; Ni DR; Cheng FC; Ho YP; Kuo JS
Neurochem Res; 1999 Jun; 24(6):719-22. PubMed ID: 10447454
[TBL] [Abstract][Full Text] [Related]
31. 2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine].
Unger EL; Mazzola-Pomietto P; Murphy DL; Andrews AM
J Pharmacol Exp Ther; 2002 Nov; 303(2):527-33. PubMed ID: 12388632
[TBL] [Abstract][Full Text] [Related]
32. Resistance to striatal dopamine depletion induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice expressing human mutant Cu,Zn superoxide dismutase.
Fornai F; Carrì MT; Ferri A; Paolucci E; Prisco S; Bernardi G; Rotilio G; Mercuri NB
Neurosci Lett; 2002 Jun; 325(2):124-8. PubMed ID: 12044637
[TBL] [Abstract][Full Text] [Related]
33. The effects of intranasal infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) upon catecholamine concentrations within olfactory bulbs and corpus striatum of male mice.
Dluzen DE; Kefalas G
Brain Res; 1996 Nov; 741(1-2):215-9. PubMed ID: 9001725
[TBL] [Abstract][Full Text] [Related]
34. Methamphetamine fails to alter the noradrenergic integrity of the heart.
Ruffoli R; Soldani P; Pasquali L; Ruggieri S; Paparelli A; Fornai F
Ann N Y Acad Sci; 2008 Oct; 1139():337-44. PubMed ID: 18991879
[TBL] [Abstract][Full Text] [Related]
35. Oral versus parenteral efficacy of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): differential effects on depletion of heart norepinephrine and of striatal dopamine in mice.
Fuller RW; Hemrick-Luecke SK
Biochem Pharmacol; 1987 Mar; 36(6):789-92. PubMed ID: 3494450
[No Abstract] [Full Text] [Related]
36. The impact of gender and estrogen on striatal dopaminergic neurotoxicity.
Miller DB; Ali SF; O'Callaghan JP; Laws SC
Ann N Y Acad Sci; 1998 May; 844():153-65. PubMed ID: 9668673
[TBL] [Abstract][Full Text] [Related]
37. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
38. Effect of 4-(4-methoxy-1,2,5-thiadiazol-3-yl)-1-methyl-1,2,3,6-tetrahydropyridine , an analog of MPTP, on mouse heart norepinephrine and brain catecholamines.
Hemrick-Luecke SK; Mitch CH; Quimby SJ; Fuller RW
Neurochem Int; 1993 Nov; 23(5):467-70. PubMed ID: 8251928
[TBL] [Abstract][Full Text] [Related]
39. Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice.
Moy LY; Albers DS; Sonsalla PK
Brain Res; 1998 Apr; 790(1-2):264-9. PubMed ID: 9593931
[TBL] [Abstract][Full Text] [Related]
40. Persistent depletion of striatal dopamine in mice by m-hydroxy-MPTP.
Fuller RW; Hemrick-Luecke SK
Res Commun Chem Pathol Pharmacol; 1986 Aug; 53(2):167-72. PubMed ID: 3764080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
